919347-67-4

Usage

Uses

Used in Organic Synthesis:
6-(4-N-BOC-PIPERAZINE-1-YL)-3-PYRIDINYL BORONIC ACID is used as a building block for the synthesis of various organic compounds due to its unique structure and functional groups.
Used in Medicinal Chemistry:
In the pharmaceutical industry, 6-(4-N-BOC-PIPERAZINE-1-YL)-3-PYRIDINYL BORONIC ACID is used as a key intermediate in the development of new drugs, leveraging its ability to selectively modify molecules and contribute to the design of novel therapeutic agents.
Used in Drug Discovery:
6-(4-N-BOC-PIPERAZINE-1-YL)-3-PYRIDINYL BORONIC ACID is employed as a valuable tool in drug discovery, where its unique properties can be utilized to explore new chemical space and identify potential drug candidates.
Used in Biological Research:
In the field of biological research, 6-(4-N-BOC-PIPERAZINE-1-YL)-3-PYRIDINYL BORONIC ACID is used as a potentially valuable tool to study biological systems, thanks to its ability to form reversible covalent bonds with certain biomolecules, facilitating the investigation of their interactions and functions.
Overall, 6-(4-N-BOC-PIPERAZINE-1-YL)-3-PYRIDINYL BORONIC ACID is a versatile and important chemical compound with applications across various industries, including organic synthesis, medicinal chemistry, drug discovery, and biological research. Its unique structure and functional groups make it a valuable asset in the development of new pharmaceutical compounds and the study of biological systems.

InChI:InChI=1S/C14H22BN3O4/c1-14(2,3)22-13(19)18-8-6-17(7-9-18)12-5-4-11(10-16-12)15(20)21/h4-5,10,20-21H,6-9H2,1-3H3

Upstream product

• 73183-34-3 bis(pinacol)diborane 
• 153747-97-8 5-Bromo-2-(4-tert-butoxycarbonylpiperazin-1-yl)pyridine 

Relevant academic research and scientific papers

PYRROLO[3,2-C]PYRIDINE DERIVATIVES AS TLR INHIBITORS

The present invention provides a heterocyclic compound having a TLR7, TLR9, TLR7/8, TLR7/9 or TLR7/8/9 inhibitory action, which is useful as an agent for the prophylaxis or treatment of autoimmune diseases, inflammatory diseases and the like, in particular, systemic lupus erythematosus, Sjogren's syndrome, rheumatoid arthritis, psoriasis, inflammatory bowel disease and the like. The present invention is a compound represented by the formula (1): wherein each symbol is as described in the specification, or a salt thereof.

HETEROCYCLIC COMPOUNDS

The present invention provides a heterocyclic compound a TLR7 and/or TLR9 and/or TLR-7/8/9 and/or TLR-7/8 and/or TLR-7/9 inhibitory action, which is useful as an agent for the prophylaxis or treatment of autoimmune diseases and/or inflammatory diseases and the like, in particular, acute decompensated heart failure, non-alcoholic steatohepatitis (NASH), IgA nephropathy, Duchenne muscular dystrophy (DMD), systemic lupus erythematosus, Sjogren's syndrome, rheumatoid arthritis, psoriasis, inflammatory bowel disease, asthma, type 1 diabetes, myasthenia gravis, hematopoetic disfunction, B-cell malignancies, transplant rejection and graft-versus-host disease, hepatocellular carcinoma (HCC) and the like. The present invention is a compound represented by the formula (1) : wherein each symbol is as described in the specification, or a salt thereof.

PYRROLO[3,2-C]PYRIDINE DERIVATIVES AS TLR INHIBITORS

The present invention provides a heterocyclic compound having a TLR7, TLR9, TLR7/8, TLR7/9 or TLR7/8/9 inhibitory action, which is useful as an agent for the prophylaxis or treatment of autoimmune diseases, inflammatory diseases and the like, in particular, systemic lupus erythematosus, Sjogren's syndrome, rheumatoid arthritis, psoriasis, inflammatory bowel disease and the like. The present invention is a compound represented by the formula (1): wherein each symbol is as described in the specification, or a salt thereof.